Aug 9, 2022 07:00AM
Jun 27, 2022 09:30AM
Jun 27, 2022 05:55AM
Jun 27, 2022 01:01AM
Jun 27, 2022 01:00AM
Jun 2, 2022 07:05AM
Jun 2, 2022 07:00AM Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
May 10, 2022 07:00AM
Mar 15, 2022 07:00AM
Mar 1, 2022 07:00AM
Jan 19, 2022 11:48AM
Jan 10, 2022 07:00AM
Dec 13, 2021 05:09AM
Dec 12, 2021 09:00AM Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
Nov 12, 2021 08:00AM
Nov 9, 2021 06:30AM
Nov 5, 2021 07:00AM
Nov 4, 2021 06:30AM
Nov 4, 2021 06:30AM
Nov 2, 2021 06:30AM
Oct 7, 2021 07:00AM Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 14, 2021 06:30AM
Aug 20, 2021 08:00AM
Aug 9, 2021 07:35AM
Aug 9, 2021 07:35AM
Aug 9, 2021 07:30AM
Aug 8, 2021 08:00PM
Aug 8, 2021 08:00PM HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
Aug 8, 2021 08:00PM
Aug 3, 2021 04:01PM
May 25, 2021 06:30AM
May 12, 2021 04:01PM
May 6, 2021 06:30AM
Apr 29, 2021 06:30AM
Mar 2, 2021 12:00PM Epizyme (EPZM) Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call
Mar 2, 2021 12:00PM
Feb 24, 2021 06:30AM
Feb 23, 2021 06:30AM
Feb 23, 2021 06:30AM
Feb 16, 2021 06:30AM
Nov 11, 2020 04:05PM
Nov 6, 2020 06:30AM Epizyme Reports Business Progress and Third Quarter 2020 Financial Results
Nov 6, 2020 06:14AM
Nov 6, 2020 06:05AM
Oct 30, 2020 06:30AM
Oct 7, 2020 06:31AM
Oct 7, 2020 06:30AM
Sep 8, 2020 06:30AM
Aug 4, 2020 06:39AM Epizyme (EPZM) Tops Q2 EPS by 3c
Aug 4, 2020 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All